# Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity

> **NCT06690905** · PHASE4 · COMPLETED · sponsor: **CR-CSSS Champlain-Charles-Le Moyne** · enrollment: 45 (actual)

## Conditions studied

- Infections
- Obesity and Obesity-related Medical Conditions

## Interventions

- **DRUG:** Piperacillin-tazobactam administered in a prolonged infusion
- **DRUG:** Piperacillin-tazobactam administered in a standard infusion

## Key facts

- **NCT ID:** NCT06690905
- **Lead sponsor:** CR-CSSS Champlain-Charles-Le Moyne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-26
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-11-27
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690905, "Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06690905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*